S
5.25
-0.07 (-1.32%)
| Penutupan Terdahulu | 5.32 |
| Buka | 5.32 |
| Jumlah Dagangan | 2,224,830 |
| Purata Dagangan (3B) | 1,679,225 |
| Modal Pasaran | 1,068,206,144 |
| Harga / Buku (P/B) | 5.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 May 2026 |
| EPS Cair (TTM) | -0.490 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.08% |
| Nisbah Semasa (MRQ) | 14.91 |
| Aliran Tunai Operasi (OCF TTM) | -95.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -56.02 M |
| Pulangan Atas Aset (ROA TTM) | -38.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Savara, Inc. | Bercampur | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.40 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.38% |
| % Dimiliki oleh Institusi | 98.53% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Savara Announces Participation in Upcoming Investor Healthcare Conferences |
| 27 Jan 2026 | Pengumuman | Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* |
| 16 Jan 2026 | Pengumuman | Savara Announces New Employment Inducement Grant |
| 08 Jan 2026 | Pengumuman | PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |